Article

Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?

Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat, 10, B-3000, Leuven, Belgium.
Medicinal Research Reviews (impact factor: 10.7). 05/2012; 32(4):765-85. DOI:10.1002/med.21267 pp.765-85
Source: PubMed

ABSTRACT Twenty years after its original discovery, tenofovir has acquired a crucial position in the fight against human immunodeficiency virus (HIV). First, tenofovir disoproxil fumarate (TDF) is not only efficacious against, and has been licensed for the treatment of HIV (AIDS), but also HBV (hepatitis B). Second, for the treatment of HIV infections, TDF can be used in combination with other anti-HIV drugs, such as emtricitabine (combination termed Truvada(®)) and Truvada can be further combined with efavirenz, rilpivirine, elvitegravir, atazanavir, or darunavir, as a single once-daily oral pill. Third, Truvada can be used prophylactically to prevent transmission of HIV infection. And fourth, to prevent sexual HIV transmission, tenofovir could also be used topically (i.e., as a vaginal gel).

0 0
 · 
0 Bookmarks
 · 
32 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

anti-HIV drugs
 
atazanavir
 
crucial position
 
HIV infection
 
HIV infections
 
human immunodeficiency virus
 
original discovery
 
rilpivirine
 
single once-daily oral pill
 
TDF
 
tenofovir
 
tenofovir disoproxil fumarate
 
Truvada
 
vaginal gel
 

Erik De Clercq